Survival analysis in patients with newly diagnosed glioblastoma using pre- and postradiotherapy MR spectroscopic imaging†
Open Access
- 7 February 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 15 (5), 607-617
- https://doi.org/10.1093/neuonc/nos334
Abstract
The objective of this study was to examine the predictive value of parameters of 3D 1H magnetic resonance spectroscopic imaging (MRSI) prior to treatment with radiation/chemotherapy (baseline) and at a postradiation 2-month follow-up (F2mo) in relationship to 6-month progression-free survival (PFS6) and overall survival (OS). Sixty-four patients with newly diagnosed glioblastoma multiforme (GBM) being treated with radiation and concurrent chemotherapy were involved in this study. Evaluated were metabolite indices and metabolite ratios. Logistic linear regression and Cox proportional hazards models were utilized to evaluate PFS6 and OS, respectively. These analyses were adjusted by age and MR scanner field strength (1.5 T or 3 T). Stepwise regression was performed to determine a subset of the most relevant variables. Associated with shorter PFS6 were a decrease in the ratio of N-acetyl aspartate to choline-containing compounds (NAA/Cho) in the region with a Cho-to-NAA index (CNI) >3 at baseline and an increase of the CNI within elevated CNI regions (>2) at F2mo. Patients with higher normalized lipid and lactate at either time point had significantly worse OS. Patients who had larger volumes with abnormal CNI at F2mo had worse PFS6 and OS. Our study found more 3D MRSI parameters that predicted PFS6 and OS for patients with GBM than did anatomic, diffusion, or perfusion imaging, which were previously evaluated in the same population of patients.Keywords
This publication has 42 references indexed in Scilit:
- Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomideNeuro-Oncology, 2009
- Proton magnetic resonance spectroscopy imaging in the study of human brain cancer2009
- Apport de l’imagerie de spectroscopie de résonance magnétique du proton et des autres imageries métaboliques à la définition des volumes cibles de radiothérapie des tumeurs gliales de l’adulte et de l’enfantCancer/Radiothérapie, 2009
- Monoclonal Antibodies Targeting Vascular Endothelial Growth FactorBioDrugs, 2009
- Treatment options for recurrent glioblastoma: pitfalls and future trendsExpert Review of Anticancer Therapy, 2009
- Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed gliomaJournal of Neuro-Oncology, 2009
- Metabolic alterations: A biomarker for radiation‐induced normal brain injury—an MR spectroscopy studyJournal of Magnetic Resonance Imaging, 2009
- Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBMJournal of Neuro-Oncology, 2008
- Prognostic value of choline and creatine in WHO grade II gliomasNeuroradiology, 2008
- Registration of images from sequential MR studies of the brainJournal of Magnetic Resonance Imaging, 1994